Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis
Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Summary
This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Official title: A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK44459 Tablets in Subjects With Idiopathic Pulmonary Fibrosis
Key Details
Gender
All
Age Range
40 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2025-01-27
Completion Date
2026-07-15
Last Updated
2025-01-13
Healthy Volunteers
No
Conditions
Interventions
HSK44459 dose 1
HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
HSK44459 dose 2
HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Placebo
Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.